Clinical trials: sponsored by British Columbia Cancer Agency
Prostatic Cancer
Dynamic Whole Body PET/ MRI
Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer…
- Trial name
- NCT04495959
- Testing
- 68Ga-HTK03149
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasms, Prostate Cancer
PSMA PET/CT for Assessment of Recurrent Prostate Cancer
Prostate cancer (PC) is the third most common cause of cancer death in men. Most patients with localized PC will be cured with surgery or radiation therapy, but up to 35% of patients will have their PC return.
- Trial name
- NCT02899312
- Testing
- PSMA PET/CT scan
- Where
- Canada
- Volunteers
- 2,244 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer Non-small Cell Stage IV, Brain Metastases
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung…
- Trial name
- NCT03769103
- Testing
- Osimertinib, Stereotactic radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer Stage IV
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
The goal of this phase 2 clinical trial is to learn if the three treatments olaparib, durvalumab and bevacizumab can treat participants with a diagnosis of stage 4 high grade serous ovarian cancer that is too advanced to undergo…
- Trial name
- NEOCATS (NCT06650709)
- Testing
- Olaparib, Bevacizumab, Durvalumab
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer, Pulmonary Nodule
Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study
The goal of this trial is to (a) identify people at high risk of lung cancer who would benefit from LDCT screening but are currently ineligible based on current lung cancer screening criteria (b) provide the framework to manage…
- Trial name
- IDEAL (NCT06628102)
- Testing
- Chest CT Scan
- Where
- Canada
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer, Ascites
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients.
- Trial name
- iMETABO (NCT05025878)
- Testing
- [U-13C]Glucose
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy.
- Trial name
- NCT04787289
- Testing
- Bevacizumab
- Where
- 2 sites in Canada
- Volunteers
- 244 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX
This is a multi-center, open-label Phase 1b study of SLC-0111 (oral) in combination with IV gemcitabine in CA IX positive subjects with mPDAC and comprises of 2 parts: Part 1: Dose Escalation Part 2: Dose Expansion
- Trial name
- SLC-0111-17-01 (NCT03450018)
- Testing
- SLC-0111, Gemcitabine Injection
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- British Columbia Cancer Agency
Cervical Dysplasia, Vulvar Dysplasia
OCT-AF Imaging of Pre-cancers of Vulva and Cervix
The multimodal imaging technology, OCT-AFI, will be used to image sites on the cervix, the endocervical canal and vulva. The imaging probe is small enough, it can be inserted into the endocervical canal for imaging.
- Conditions
- Cervical Dysplasia, Vulvar Dysplasia, Precancerous Lesions, Vulvar Cancer
- Trial name
- NCT03285841
- Testing
- OCT-AFI
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Precancerous Condition, Cervical Cancer
Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
The goal of this proposal is to determine whether a hand-held confocal microscopy probe may perform better than standard methods in detecting cancer or pre-cancerous abnormalities of the cervix.
- Trial name
- Confocal (NCT02574442)
- Testing
- In Vivo Confocal Microscopy Probe
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Case Crossover Study of Intermittent Fasting in CLL/SLL
The purpose of this study is to compare the 16/8 intermittent fasting method with the 5:2 Method in a subset of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma at BC Cancer- Victoria.
- Trial name
- NCT05708326
- Testing
- 5:2 Method (intermittent fasting regimen), 16/8 Method (intermittent fast regimen)
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- British Columbia Cancer Agency
Bone Metastases
Diagnostic CT Palliative Radiotherapy: Feasibility Study of Treating Bone Metastases Without a CT Simulation
The purpose of this non-randomized, prospective study is to assess the feasibility of planning and delivering conventional palliative radiotherapy to bone metastases on previously available diagnostic CT scans (dCT).
- Trial name
- dCT-PRT (NCT06235034)
- Testing
- Diagnostic CT
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Endometrial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer
Endometrial cancer(EC) is the 4th most common cancer in women globally. Clinicians struggle to determine 'the best' treatment for endometrial cancers as they are very hard to tell apart under the microscope.
- Trial name
- TAPER (NCT04705649)
- Testing
- Treatment de-escalation
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- British Columbia Cancer Agency
Brain Metastases
Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases
Radiotherapy to the whole brain is standard treatment for cancer that has spread to the brain (brain metastases) as it treats both the metastases that can be seen on scans and the brain metastases that are too small to be seen on…
- Trial name
- NCT01046123
- Testing
- whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer Female, Hormone Receptor Positive Tumor
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis.
- Trial name
- LALEAST (NCT03917082)
- Testing
- Tamoxifen Citrate
- Where
- Canada
- Volunteers
- 290 people
- Sponsor
- British Columbia Cancer Agency
Hepatocellular Carcinoma, Liver Cirrhosis
FDGal PET/CT to Detect Hepatocellular Carcinoma
Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Liver Disease
- Trial name
- NCT02899325
- Testing
- Diagnostic PET/CT scans
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Hyperthyroidism
A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients
The purpose of this study is to evaluate technetium-99m (99mTc) pertechnetate produced by a cyclotron as a replacement for 99mTc pertechnetate obtained from a generator containing the parent isotope Molybdenum-99 (99Mo).
- Trial name
- NCT02514187
- Testing
- Cyclotron-produced 99mTc, Generator-produced 99mTc
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, Carcinoid Tumor
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT04915144
- Testing
- 177Lu-DOTATOC
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency